Khartis Therapeutics has raised $50 million in a Series B funding round led by Forge Life Science Partners to advance its oral small molecule immunology pipeline.
Amount Raised
$50 Million
Round Type
Series B
San DiegoBiotechnologyHealth CareTherapeuticsInvestors
Description
Khartis Therapeutics, a biotechnology company, has emerged from stealth mode with a successful Series B financing round. The company raised $50 million to advance its development of oral small molecule medicines targeting immunological and chronic diseases. This funding round saw participation from notable investors such as Longwood Fund and Alexandria Venture Investments, along with existing supporters. The new capital will help propel the company's innovative pipeline forward.
Quick answer
Khartis Therapeutics raised $50 Million in a Series B round, dated August 13, 2026. Investors: Nextech Invest, Lilly Asia Ventures, Foresite Capital, Longwood Fund, Alexandria Venture Investments and Forge Life Science Partners. Khartis Therapeutics is based in San Diego, California, United States.
- How much did Khartis Therapeutics raise?
- Khartis Therapeutics raised $50 Million in a Series B round on August 13, 2026.
- Who invested in Khartis Therapeutics?
- Nextech Invest, Lilly Asia Ventures, Foresite Capital, Longwood Fund, Alexandria Venture Investments and Forge Life Science Partners are named as investors in this round.
- What does Khartis Therapeutics do?
- Khartis Therapeutics is a biotechnology company focused on developing first- and best-in-class oral small molecule medicines aimed at treating immunological and chronic diseases.
- Where is Khartis Therapeutics based and how big is it?
- Khartis Therapeutics is based in San Diego, California, United States. Fundz records about 14 employees.
- Who are the decision-makers at Khartis Therapeutics?
- Fundz holds 2 contacts at Khartis Therapeutics, including the Co-founder & Chief Scientific Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Khartis Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- AvenCell Therapeutics raised $47M (Series C) on September 27, 2026.
- Nuclidium raised $121M on September 26, 2026.
- Rejuvenation Technologies raised an undisclosed amount on September 24, 2026.
- Kasvu Therapeutics raised $34M (Series A) on September 24, 2026.
- ViferaXS raised $14M (Series A) on September 23, 2026.
- Kinoxis Therapeutics raised $5M (Seed) on September 23, 2026.
Who to call at Khartis Therapeutics, and when
A new round usually means Khartis Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Khartis Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Khartis Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Khartis Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Khartis Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansKhartis Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.